SHE:002004

3 stories mentioning SHE:002004Updated 13d ago

Every FINWIRES story that references SHE:002004, newest first.

Huapont Life Sciences Gets NMPA Nod for Ibrutinib Tablets

Huapont Life Sciences (SHE:002004) obtained drug registration from China's medical products administrator for ibrutinib tablets, according to a weekend filing with the Shenzhen bourse.The drug is indicated for mantle cell lymphoma, chronic lymphocytic leukemia and Waldenström's macroglobulinemia.The company said this marks its first self-developed innovative drug to receive NMPA registration.Shares of the chemical products manufacturer closed 2% higher Monday.

SHE:002004

Asia100d ago

Huapont Life Sciences Unit Gets Registration Certificate for Upadacitinib Tablets

Huapont Life Sciences' (SHE:002004) unit, Chongqing Huabang Pharmaceutical, obtained a drug registration certificate for upadacitinib extended-release tablets, according to a Friday disclosure on the Shenzhen bourse.The drug is used to treat various conditions such as atopic dermatitis, rheumatoid arthritis and ulcerative colitis.

SHE:002004

Asia102d ago

Huapont Life Sciences Subsidiary Hit with 46 Million Yuan Fine for Overdue Tax Payments

China's tax regulator imposed a fine of 46.1 million yuan on Huapont Life Sciences' (SHE:002004) subsidiary, Shenyang Xinma Pharmaceutical, for overdue tax payments, according to a Wednesday disclosure on the Shenzhen bourse.The period of the penalties was from between Jan. 1, 2019, and Dec. 31, 2024.The pesticide chemical product manufacturer's shares fell by less than 2% at the close.

SHE:002004

Track with the FINWIRES app suite

FolioX

Track SHE:002004 in your portfolio

WheelAI

Analyze SHE:002004 options with the wheel strategy

StockInsider

See market sentiment on SHE:002004